Key facts
- Pneuma Respiratory’s last known valuation is $115.0M (Dec 2018).
- It has raised $44.1M across 8 recorded rounds; the latest was Seed Round ($3.3M) in Feb 2025.
- Notable investors include DEFTA Partners, Haisco Pharmaceutical Group Company, High Country Impact Fund.
- Pneuma Respiratory has filed 20 Form Ds with the SEC since 2018, most recently Dec 2025 ($3.0M sold to 26 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 8 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Pneuma Respiratory
Funding rounds
8 roundsAbout Pneuma Respiratory
Developer of a digital breath-activated inhaler designed to provide therapeutic treatments for lung diseases. The company's inhaler combines a differential pressure sensor that detects airflow by measuring the pressure drop when a patient inhales through it, enabling patients to receive a potent digital inhaler for lung diseases.
- Sector
- Healthcare
- HQ
- Boone, NC, United States
- Founded
- 2015
- Employees
- 11
- Website
- pneumarespiratory.com/
- Ownership
- Privately Held (backing)
Pneuma Respiratory doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pneuma Respiratory shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pneuma Respiratory in its N-PORT filings yet. We sweep new filings monthly.